ArticleTranslational cancer research2026
Machine learning-based early survival prediction in early-onset hepatocellular carcinoma: a SEER-based multi-model comparative study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-onset hepatocellular carcinoma (eHCC) presents distinct clinical challenges; however, prognostic determinants remain inadequately characterized. This study aimed to develop and validate machine learning (ML) models to predict early survival in patients with eHCC and to identify key prognostic factors. Methods: Patients diagnosed with eHCC were identified from the Surveillance, Epidemiology, and End Results (SEER) database [2010-2021] based on predefined inclusion criteria. The cohort was randomly partitioned into training (70%) and validation (30%) sets. Five ML algorithms were implemented: multilayer perceptron (MLP), logistic regression (LR), support vector machine (SVM), random forest (RF), and extreme gradient boosting (XGBoost). Additionally, a conventional model based on the American Joint Committee on Cancer (AJCC) staging system was constructed as a benchmark for comparison with the ML-based models. Model discrimination was assessed by the area under the receiver operating characteristic curve (AUC). Calibration curves and complementary metrics quantified predictive accuracy. The SHapley Additive exPlanations (SHAP) framework was employed to rank variable importance and interpret model predictions. Results: A total of 1,922 patients with eHCC were included, of whom 1,345 were assigned to the training cohort and 577 to the validation cohort. Thirteen clinicopathological and treatment-related variables were incorporated into the analysis, including age, sex, race, pathological grade, surgical status, AJCC stage, SEER stage, tumor size, alpha-fetoprotein (AFP) level, marital status, radiotherapy, chemotherapy, and macrovascular invasion. The RF model demonstrated optimal performance in the validation cohort, achieving an AUC of 0.80, accuracy of 0.72, precision of 0.71, recall of 0.81, and F1 score of 0.75. This substantially outperformed the AJCC staging-based model with AUC of 0.66, representing a ΔAUC of 0.14 and 21.2% relative improvement. SHAP analysis identified surgical intervention as the dominant predictor in the RF model. Conclusions: The RF model demonstrated robust discriminative ability for predicting early survival in eHCC patients. This validated model can facilitate risk stratification and inform individualized therapeutic decisions for patients with eHCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.